Wang Shangzeng, Liu Xiaoya, He Zike, Chen Xinfeng, Li Wei
Department of Orthopaedics, Second Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou, 450002, China.
Department of Orthopaedics, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, 450002, China.
Tumour Biol. 2016 Jan;37(1):1205-10. doi: 10.1007/s13277-015-3830-3. Epub 2015 Aug 18.
Patients with osteosarcoma have poor prognosis and are often at high risk of death. Identification of prognostic biomarkers for osteosarcoma may aid in improving the survival. Hyperuricemia had been suggested as a poor prognostic factor of several cancers, but the prognostic role of hyperuricemia in osteosarcoma patients had not been assessed. In the present study, we investigated the prognostic role of hyperuricemia at baseline on the overall survival of patients with osteosarcoma. Sixty osteosarcoma patients with hyperuricemia were matched (1:2) to 120 osteosarcoma patients without hyperuricemia with similar age and gender. Data from those patients with osteosarcoma were evaluated retrospectively. The role of hyperuricemia on overall survival was firstly analyzed using the Kaplan-Meier method. Univariate and multivariate Cox regression models were also used to further evaluate the prognostic significance of hyperuricemia. None of the clinicopathological parameters except distant metastasis was associated with hyperuricemia. Kaplan-Meier method showed that patients with hyperuricemia had shorter overall survival compared with those with normouricemia (P < 0.0001, log-rank test). In univariate analysis, hyperuricemia was associated with poorer overall survival in osteosarcoma patients (HR = 2.71, 95 % CI 1.75-4.20; P < 0.0001). In the multivariate analysis, after adjusting for age, gender, serum alkaline phosphatase, stage, tumor size, and metastasis, hyperuricemia was independently associated with poorer overall survival in osteosarcoma patients (HR = 2.28, 95 % CI 1.41-3.69; P = 0.001). In conclusion, hyperuricemia at baseline is associated with poorer overall survival in osteosarcoma patients, and it has an adverse impact on the prognosis of osteosarcoma patients.
骨肉瘤患者预后较差，且往往面临较高的死亡风险。识别骨肉瘤的预后生物标志物可能有助于提高生存率。高尿酸血症已被认为是几种癌症的不良预后因素，但高尿酸血症在骨肉瘤患者中的预后作用尚未得到评估。在本研究中，我们调查了基线时高尿酸血症对骨肉瘤患者总生存期的预后作用。将60例高尿酸血症骨肉瘤患者与120例年龄和性别相似的非高尿酸血症骨肉瘤患者进行匹配（1:2）。对这些骨肉瘤患者的数据进行回顾性评估。首先使用Kaplan-Meier方法分析高尿酸血症对总生存期的作用。还使用单因素和多因素Cox回归模型进一步评估高尿酸血症的预后意义。除远处转移外，没有其他临床病理参数与高尿酸血症相关。Kaplan-Meier方法显示，高尿酸血症患者的总生存期比尿酸正常患者短（P < 0.0001，对数秩检验）。在单因素分析中，高尿酸血症与骨肉瘤患者较差的总生存期相关（HR = 2.71，95%CI 1.75 - 4.20；P < 0.0001）。在多因素分析中，在调整年龄、性别、血清碱性磷酸酶、分期、肿瘤大小和转移后，高尿酸血症与骨肉瘤患者较差的总生存期独立相关（HR = 2.28，95%CI 1.41 - 3.69；P = 0.001）。总之，基线时的高尿酸血症与骨肉瘤患者较差的总生存期相关，并且对骨肉瘤患者的预后有不利影响。
